Greenland Mines Ltd
GRML
Greenland Mines Ltd (the Company or Greenland Mines ), formerly known as Klotho Neurosciences, Inc., develops essential medicines for the treatment of chronic diseases cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a …
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$33M
▼ -71.6% YoY
Op. Margin
–
ROIC
-36.20%
▲ +188.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$24M
▼ -99.9% YoY
Net Debt
-$57M
Net Cash Position
Cash & Equiv.
$57M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with GRML
Greenland Mines (GRML) in two numbers
Questions about Greenland Mines
Does Greenland Mines (GRML) pay a dividend?
No. Greenland Mines (GRML) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in GRML's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GRML
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.